Catalyst Pharmaceuticals, Inc. (CPRX) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Biotechnologie Branche. Der Hauptsitz des Unternehmens ist in Coral Gables, FL, United States. Der aktuelle CEO ist Richard John Daly.
CPRX hat IPO-Datum 2006-11-08, 181 Vollzeitbeschäftigte, gelistet an der NASDAQ Capital Marke, eine Marktkapitalisierung von $3.22B.
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company headquartered in Coral Gables, Florida, specializing in therapies for rare neuromuscular and neurological diseases. The company's primary product, Firdapse (amifampridine phosphate), is approved for treating Lambert-Eaton Myasthenic Syndrome (LEMS) in adults, while its pediatric formulation, Ruzurgi, addresses LEMS in children. Catalyst is advancing Firdapse through clinical development for additional indications including MuSK antibody positive myasthenia gravis, spinal muscular atrophy type 3, and hereditary neuropathy with liability to pressure palsies. The company maintains strategic partnerships with BioMarin Pharmaceutical Inc. and Endo Ventures Limited for product development and commercialization efforts.
